文献速递临床生化质量管理与危急值

提高临床化学检验自动化并支持可靠解读的模型

A model to increase automation and support reliable interpretation of clinical chemistry tests.
PubMed 文献 · Clin Chem Lab Med · 2026-05-11

结果显示多数分析物手动稀释被消除、成本降低、效率提升,P90周转时间在多数分析物中下降,仅LDH在2025年残留手动稀释率为每1000次检测3.38次。

要点

  • 对超出预设自动化限值的分析物定义报告上限,可减少不必要的手动稀释。
  • LDH因肿瘤随访需精确报告,2025年手动稀释残留率为每1000次检测3.38次。
  • 多数分析物在2023至2025年间高于切值样本的P90周转时间下降。

核心结论

  • 修订验证规则以在预设阈值以上报告结果,可提供临床有意义信息并减少不必要手动操作。
  • 该模型通过提升流程自动化、一致性和决策支持,改善效率并支持合理患者管理。

研究设计与样本

  • 实施多步骤工作流,包括文献回顾、临床医生与员工参与、定义报告上限、中间件定制及回顾性与前瞻性性能评估。

主要发现

  • 文献回顾和临床反馈支持定义报告上限,超过该上限通常不要求精确值,但LDH因肿瘤随访需精确报告例外。
  • 新规则实施后消除了大多数手动稀释,显著降低成本并提升效率。
  • 2023至2025年间,多数分析物高于切值样本的P90周转时间下降。
  • 2025年LDH是唯一未完全消除手动稀释的分析物,残留率为每1000次检测3.38次(2023年为每1000次7.32次)。
  • 临床反馈确认新报告规则适当。

关键数值与推荐

  • 十五项分析物需在预设自动化限值以上进行手动稀释。
  • LDH在2025年手动稀释残留率为每1000次检测3.38次,2023年为每1000次7.32次。
  • LDH因肿瘤随访需要精确报告,未纳入常规报告上限规则。

临床怎么用

  • 检验科可审查超线性范围项目,与临床沟通定义报告上限以减少不必要稀释。
  • 通过中间件定制自动化规则,对超过报告上限的结果按切值报告并自动释放。
  • 对需精确值的特定项目(如肿瘤随访中的LDH)保留手动稀释流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Pathological conditions may result in clinical chemical values exceeding the linearity range of laboratory methods. In clinical practice, not all tests require exact numerical values for patient management, as useful information can still be provided when results are reported to a defined cutoff. This study describes an approach to reduce unnecessary dilutions by identifying tests that can be reported above a defined threshold. METHODS: Eighty-six clinical chemistry assays on Cobas 8000 (middleware: Infinity) were reviewed at the Laboratory Medicine of the University Hospital of Padua. Fifteen analytes requiring manual dilution beyond predefined automated limits were selected. A multi-step workflow was implemented, including literature review, clinician and staff engagement, definition of upper reporting limits, middleware customisation, and retrospective and prospective performance evaluation. Key outcomes included turnaround time (TAT), auto-release rate, manual dilution frequency, estimated costs, and clinician requests for exact values. RESULTS: Literature review and clinician feedback supported the definition of upper reporting limits beyond which exact values were not routinely required, except for lactate dehydrogenase (LDH), where oncologic follow-up necessitated precise reporting. Implementation of the new rules eliminated most manual dilutions, substantially reducing costs and improving efficiency. P90 TAT decreased for samples above cutoff values in most analytes between 2023 and 2025. LDH was the only analyte for which manual dilution was not completely eliminated in 2025, with a residual rate of 3.38 per 1000 tests (vs. 7.32 per 1000 in 2023). Clinician feedback confirmed the appropriateness of the new reporting rules. CONCLUSIONS: This study shows that revising validation rules to report results above predefined thresholds provides clinically meaningful information while reducing unnecessary manual procedures. This model supports appropriate patient management and improves efficiency by enhancing process automation, consistency, and decision-making.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Falda A, Bernardi D, Moz S, et al. A model to increase automation and support reliable interpretation of clinical chemistry tests. Clin Chem Lab Med. 2026. PMID: 42107064. doi:10.1515/cclm-2025-1727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。